Fortress Biotech
FBIO
64 hedge funds and large institutions have $25.8M invested in Fortress Biotech in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 9 closing their positions.
0.05% less ownership
Funds ownership: 1.91% → 1.86% (-0.05%)
0% less capital invested
Capital invested by funds: $25.9M → $25.8M (-$58.9K)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
3% less funds holding
Funds holding: 66 → 64 (-2)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$850K |
| 2 |
1WM
1900 Wealth Management
San Antonio,
Texas
|
+$99.8K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$77.9K |
| 4 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$52.5K |
| 5 |
SAM
Shikiar Asset Management
New York
|
+$41.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$558K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$495K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$248K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$199K |
| 5 |
E
Ergoteles
New York
|
-$125K |
FBIO Hedge Fund Activity: Q3 2022 in Review
64 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q3 2022, worth a combined $25.8M — down 0.23% from $25.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FBIO and 8 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 16 added.
The largest buyer was Tang Capital Management, adding an estimated $850K. The largest seller was Millennium Management, cutting an estimated $558K.
- 64 institutional investors held Fortress Biotech (FBIO) as of Q3 2022, down from 66 in Q2 2022.
- Funds reported $25.8M of Fortress Biotech stock for Q3 2022, down 0.23% quarter-over-quarter.
- 8 funds opened new Fortress Biotech positions in Q3 2022 and 9 closed out, a net change of -1 holder.
- The largest Fortress Biotech buyer in Q3 2022 was Tang Capital Management, an estimated $850K added.
- The largest Fortress Biotech seller in Q3 2022 was Millennium Management, an estimated $558K sold.
Based on aggregated 13F filings for Q3 2022.